Surgical Oncology Program, Endocrine Surgery Section, National Cancer Institute, NIH, 10 Center Drive, Building 10 - Room 45952, Bethesda, MD 20892, USA.
Surgical Oncology Program, Endocrine Surgery Section, National Cancer Institute, NIH, 10 Center Drive, Building 10 - Room 45952, Bethesda, MD 20892, USA.
Surg Oncol Clin N Am. 2023 Apr;32(2):315-325. doi: 10.1016/j.soc.2022.10.008.
Multiple endocrine neoplasia type 1 syndrome (MEN1) is a disease caused by mutations in the MEN1 tumor suppressor gene leading to hyperparathyroidism, pituitary adenomas, and entero-pancreatic neuroendocrine tumors. Pancreatic neuroendocrine tumors (PNETs) are a major cause of mortality in patients with MEN1. Identification of consistent genotype-phenotype correlations has remained elusive, but MEN1 mutations in exons 2, 9, and 10 may be associated with metastatic PNETs; patients with these mutations may benefit from more intensive surveillance and aggressive treatment. In addition, epigenetic differences between MEN1-associated PNETs and sporadic PNETs are beginning to emerge, but further investigation is required to establish clear phenotypic associations.
多发性内分泌腺瘤 1 型综合征(MEN1)是一种由 MEN1 肿瘤抑制基因的突变引起的疾病,导致甲状旁腺功能亢进、垂体腺瘤和肠胰神经内分泌肿瘤。胰腺神经内分泌肿瘤(PNETs)是 MEN1 患者死亡的主要原因。虽然一直未能确定一致的基因型-表型相关性,但 MEN1 突变在外显子 2、9 和 10 中可能与转移性 PNET 相关;这些突变的患者可能受益于更密集的监测和积极治疗。此外,MEN1 相关 PNETs 和散发性 PNETs 之间的表观遗传差异开始显现,但需要进一步研究以建立明确的表型相关性。